Physician profile
Patricia Park
NPI 1700098282
$2,197.02
in general payments reported to CMS, 2019-2025
23 companies · $1,259 in 2025
The $1,259 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $205 · 2023: $250 · 2024: $482 · 2025: $1,259.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,992.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,991.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Insulet Corporation | $349.99 | 2025 | Omnipod |
| Amgen INC. | $273.56 | 2025 | Tepezza, Repatha |
| Lilly USA, LLC | $259.47 | 2022-2023 | Mounjaro, Baqsimi, Lyumjev |
| Janssen Biotech, INC. | $219.75 | 2024 | Stelara, Tremfya, Simponi |
| Novo Nordisk INC | $115.87 | 2023 | Wegovy |
| Boston Scientific Corporation | $114.47 | 2025 | Axonics |
| Medtronic, INC. | $112.69 | 2024 | Minimed 780g |
| Tandem Diabetes Care, INC. | $108.68 | 2023-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Bayer Healthcare Pharmaceuticals INC. | $81.34 | 2025 | |
| Xeris Pharmaceuticals, INC. | $80.40 | 2023-2025 | Recorlev, Gvoke Hypopen |
| Abbvie INC. | $76.94 | 2024-2025 | |
| Recordati_rare_diseases_inc. | $67.69 | 2025 | Isturisa |
| Dexcom, INC. | $62.00 | 2022-2025 | Dexcom G6 Transmitter |
| Evoke Pharma, INC. | $48.81 | 2025 | |
| Corcept Therapeutics | $41.67 | 2025 | Korlym |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mannkind Corporation | $33.08 | 2025 | |
| Neurocrine Biosciences, INC. | $30.68 | 2024 | |
| Qol Medical, LLC | $27.26 | 2022-2024 | Sucraid |
| Kyowa Kirin, INC. | $26.78 | 2025 | |
| Phathom Pharmaceuticals, INC. | $20.25 | 2023 | Voquezna |
| Sanofi-Aventis U.S. LLC | $17.59 | 2025 | |
| Intercept Pharmaceuticals, INC. | $14.31 | 2025 | |
| Acella Pharmaceuticals, LLC | $13.74 | 2025 | NP Thyroid 60 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patricia Park listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.